 Kura Oncology NASDAQ:KURA was downgraded by Zacks Investment Research from a buy rating to a hold rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. ... 